Idiopathic Pulmonary Fibrosis (IPF) Treatment and Prognosis: A Comprehensive Review

Authors

  • Mohammed Ali Alshahrani Respiratory therapist, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
  • Mosa Theeban Al Garni Respiratory therapist, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
  • Yousef Ali Alzamil Respiratory therapist, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
  • Khaled Jobran Alshahrani Respiratory therapist, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
  • Mohammed Saad Alahmari Respiratory therapist, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
  • Abdullah Ahmed Albeair Respiratory therapist, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
  • Mohammed Abdullah Alamri Respiratory therapist, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
  • Eyad Hassan Jaber Alkadi Respiratory therapist, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
  • Mohammed Moshabbab Alahmari Respiratory therapist, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia

DOI:

https://doi.org/10.63278/1360

Keywords:

idiopathic pulmonary fibrosis, prognostic factors, treatment, monitoring, follow-up

Abstract

Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause, is the most common and deadly of the idiopathic interstitial pneumonias. With a median survival of 3–5 years following diagnosis, IPF is characterized by a progressive decline in lung function and quality of life in most patients. Prognostic factors recognized classically that influence mortality include functional, clinical and radiological parameters. However, in recent years, there has also been progress in the knowledge of genetic factors and biomarkers that may be useful in the prognostic evaluation of these patients. On the other hand, the monitoring of the disease throughout its evolution is key to improving the prognosis of the patients, as it allows for taking therapeutic measures based on this evolution, even early remission for lung transplantation. This article reviews the main prognostic factors of the disease, as well as the most useful way to monitor the disease follow-up.

Downloads

Published

2024-12-14

How to Cite

Mohammed Ali Alshahrani, Mosa Theeban Al Garni, Yousef Ali Alzamil, Khaled Jobran Alshahrani, Mohammed Saad Alahmari, Abdullah Ahmed Albeair, Mohammed Abdullah Alamri, Eyad Hassan Jaber Alkadi, and Mohammed Moshabbab Alahmari. 2024. “Idiopathic Pulmonary Fibrosis (IPF) Treatment and Prognosis: A Comprehensive Review ”. Metallurgical and Materials Engineering 30 (4):667-76. https://doi.org/10.63278/1360.

Issue

Vol. 30 No. 4 (2024)

Section

Research

License

Copyright (c) 2025 Mohammed Ali Alshahrani, Mosa Theeban Al Garni, Yousef Ali Alzamil, Khaled Jobran Alshahrani, Mohammed Saad Alahmari, Abdullah Ahmed Albeair, Mohammed Abdullah Alamri, Eyad Hassan Jaber Alkadi, Mohammed Moshabbab Alahmari

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  • Authors are permitted and encouraged to post their published articles online (e.g., in institutional repositories or on their website, social networks like ResearchGate or Academia), as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

 

Creative Commons License
Except where otherwise noted, the content on this site is licensed under a Creative Commons Attribution 4.0 International License.